Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We sought to determine the frequency of BRAF mutations in human lung cancer pathogenesis.
|
12460919 |
2002 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although >90% of BRAF mutations in melanoma involve codon 599 (57 of 60), 8 of 9 BRAF mutations reported to date in NSCLC are non-V599 (89%; P < 10(-7)), strongly suggesting that BRAF mutations in NSCLC are qualitatively different from those in melanoma; thus, there may be therapeutic differences between lung cancer and melanoma in response to RAF inhibitors.
|
12460918 |
2002 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
We sought to determine the frequency of BRAF mutations in human lung cancer pathogenesis.
|
12460919 |
2002 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
|
31711466 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.
|
30224342 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Consistent with earlier reports, our results show that KRAS and BRAF mutation frequencies in colorectal cancer were 44.3% and 13.0%, respectively, while EGFR mutations were detected in 11.1% of the lung cancer specimens.
|
21943394 |
2011 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.
|
28203297 |
2017 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
|
22649091 |
2012 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data, together with the nonoverlapping pattern of EGFR and BRAF mutations in human lung cancer, suggest that these lesions define distinct clinical entities whose treatment should be guided by prospective real-time genotyping.
|
19010912 |
2008 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear.
|
24035431 |
2013 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We developed a highly sensitive LUNG CANCER (LC)-biochip approach for the detection of the most common EGFR, KRAS, PIK3CA, and BRAF gene mutations.
|
25153497 |
2015 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutated lung cancer is a genetically distinct subtype that occurs in 2-5% of non-small cell lung carcinomas (NSCLC).
|
28625649 |
2017 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma.
|
21483012 |
2011 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We conducted a retrospective multicenter cohort study in Europe of patients with advanced BRAF-mutant lung cancer treated with known BRAF inhibitors.
|
26200454 |
2015 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ATM loss also enhances the sensitivity of KRAS- or BRAF-mutant lung cancer cells to MEK inhibition.
|
27922010 |
2016 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
|
27834212 |
2016 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The role of KRAS and BRAF mutations and ALK rearrangement in lung cancer-targeted therapy, are also reviewed.
|
21463141 |
2011 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutated lung cancer is relatively aggressive and is resistant to currently available therapies.
|
25706985 |
2015 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Combined genomic and proteomic analyses demonstrated infrequent alteration of validated lung cancer targets (including the absence of BRAF mutations in TTF1-negative LUAD), but identified novel potential targets for TTF1-negative LUAD, including KEAP1/Nrf2 and DNA repair pathways.
|
25878335 |
2015 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that AZ628 has greater potential than Dabrafenib, both as a single agent and combined with Trametinib, for the treatment of non-V600 BRAF mutant lung cancer.
|
29662630 |
2018 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.
|
28947956 |
2017 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
|
29516752 |
2018 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our clinical data suggest that BRAF mutations define specific subsets of patients with NSCLC; while their oncogenic nature is yet to be established in lung cancer, especially for non-V600E mutations, the value of BRAF mutations to predict the efficacy of targeted agents remains unclear.
|
26711930 |
2016 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study, using both novel and established technologies, we developed a clinically practical assay to survey the status of three frequently mutated genes in lung cancer (EGFR, K-ras and TP53) and two genes (BRAF and β-catenin) with known hotspot mutations in many other cancers.
|
22407457 |
2012 |